Drug Development 2017 –
Advancing early phase clinical trials through collaboration
This event is supported by the Cancer Institute NSW and by the following sponsors
FINAL PROGRAM- Thursday 23rd March 2017
NAB Auditorium, Garvan Institute of Medical Research
384 Victoria St, Darlinghurst NSW 2010
8:00am: Registration opens
830am: Welcome by Anthony Joshua, Kinghorn Cancer Centre
840am: Moving Forward in NSW – Dr Kerry Chant, Chief Medical Officer NSW
850am: NSW Cancer Institute and Early Phase Trials– Dr David Currow, Chief Cancer Officer NSW
900am: Plenary I: Trends in Early Phase Clinical Trials – Dr Geoff Shapiro – Dana Farber, Boston
Session 1: Collaborative Landscape
Chair: Goldstein
950am: Cancer Trials Australia- Dr Jayesh Desai, Peter MacCallum Cancer Centre
1010am: NECTA – Dr Lisa Horvath, Lifehouse
1030am: Morning Tea
Session 2a: How do we get things going in Oncology? (In parallel)
Chair: Tran
1050am: Plenary IIa: Organizing a phase 1 unit, Teamwork Matters- Prof Lillian Siu, Princess Margaret Cancer Centre
1140pm: Getting it going in Melbourne – How I did it - Dr Hui Gan, Olivia Newton John Cancer Centre
1200pm: The Korean Experience – Dr KP Kim, Asan Medical Centre, Seoul, Korea
1220pm: The Scientia Model - Dr Charlotte Lemech, Scientia Clinical Research
1240pm: The Perth Experience – Dr Michael Millward, Sir Charles Gardiner Hospital
1-130pm: Panel Discussion – all above
Session 2b: Early Phase in the General Medicine (in parallel) (Garvan Boardroom, Level 5)
Chair: Cunningham
1050am: Plenary IIb: Establishing a NIH trials network outside the USA - Dr Mark Polizotto, Kirby Institute
1120pm: Looking forward at UNSW – Ms Lisa Nelson, Scientia Clinical Research
1145pm: Developing protein biopharmaceuticals to treat obesity related disease: from concept to clinic – Dr Mark Febbraio, Garvan Institute
1210pm: Antibody Therapies in the Clinic – Dr Daniel Christ, Garvan Institute
1235pm: Pharmacokinetics in drug development - more haste less speed– Dr Jennifer Martin, University of Newcastle
1:30pm: Lunch & Posters
Session 3A – How do you get the right patient? Where are we going?
Chair: Markman/ Horvath
200pm: CTDNA – Tool of the future? Dr Arun Azad, Monash Health
220:pm: Pharmacokinectics Tools for Early Phase Trials- Dr Steven Ackland, University of Newcastle
240pm: CTCs in Practice – Dr Paul DeSouza, Liverpool Hospital
3pm: Metformin and Perspectives on Dose Escalation - Dr Ric Day, St Vincents Hospital
320pm Afternoon Tea
Session 3B – Whats been achieved in the Australian Environment
Chair: Lemech
340 pm: miRNA therapeutics in the clinic – Dr Glen Reid, University of Sydney
420pm: Screening in Practice – Dr Ben Tran, PeterMaccullum Cancer Centre
440pm: Imaging / Theragnostics in Early Phase Trials – Dr Louise Emmett, St Vincents Hospital
5pm: Westmead experience in I/O phase 1 – Challenges and Solutions – Dr Matteo Carlino, Westmead Hospital
520pm: What we want from an early phase group and what are the metrics we use? - David Fuller, INC Research
540pm: Industry Perspective on early phase trials collaboration – Dr Amanda Goldrick, Amgen
Advancing early phase clinical trials through collaboration
This event is supported by the Cancer Institute NSW and by the following sponsors
FINAL PROGRAM- Thursday 23rd March 2017
NAB Auditorium, Garvan Institute of Medical Research
384 Victoria St, Darlinghurst NSW 2010
8:00am: Registration opens
830am: Welcome by Anthony Joshua, Kinghorn Cancer Centre
840am: Moving Forward in NSW – Dr Kerry Chant, Chief Medical Officer NSW
850am: NSW Cancer Institute and Early Phase Trials– Dr David Currow, Chief Cancer Officer NSW
900am: Plenary I: Trends in Early Phase Clinical Trials – Dr Geoff Shapiro – Dana Farber, Boston
Session 1: Collaborative Landscape
Chair: Goldstein
950am: Cancer Trials Australia- Dr Jayesh Desai, Peter MacCallum Cancer Centre
1010am: NECTA – Dr Lisa Horvath, Lifehouse
1030am: Morning Tea
Session 2a: How do we get things going in Oncology? (In parallel)
Chair: Tran
1050am: Plenary IIa: Organizing a phase 1 unit, Teamwork Matters- Prof Lillian Siu, Princess Margaret Cancer Centre
1140pm: Getting it going in Melbourne – How I did it - Dr Hui Gan, Olivia Newton John Cancer Centre
1200pm: The Korean Experience – Dr KP Kim, Asan Medical Centre, Seoul, Korea
1220pm: The Scientia Model - Dr Charlotte Lemech, Scientia Clinical Research
1240pm: The Perth Experience – Dr Michael Millward, Sir Charles Gardiner Hospital
1-130pm: Panel Discussion – all above
Session 2b: Early Phase in the General Medicine (in parallel) (Garvan Boardroom, Level 5)
Chair: Cunningham
1050am: Plenary IIb: Establishing a NIH trials network outside the USA - Dr Mark Polizotto, Kirby Institute
1120pm: Looking forward at UNSW – Ms Lisa Nelson, Scientia Clinical Research
1145pm: Developing protein biopharmaceuticals to treat obesity related disease: from concept to clinic – Dr Mark Febbraio, Garvan Institute
1210pm: Antibody Therapies in the Clinic – Dr Daniel Christ, Garvan Institute
1235pm: Pharmacokinetics in drug development - more haste less speed– Dr Jennifer Martin, University of Newcastle
1:30pm: Lunch & Posters
Session 3A – How do you get the right patient? Where are we going?
Chair: Markman/ Horvath
200pm: CTDNA – Tool of the future? Dr Arun Azad, Monash Health
220:pm: Pharmacokinectics Tools for Early Phase Trials- Dr Steven Ackland, University of Newcastle
240pm: CTCs in Practice – Dr Paul DeSouza, Liverpool Hospital
3pm: Metformin and Perspectives on Dose Escalation - Dr Ric Day, St Vincents Hospital
320pm Afternoon Tea
Session 3B – Whats been achieved in the Australian Environment
Chair: Lemech
340 pm: miRNA therapeutics in the clinic – Dr Glen Reid, University of Sydney
420pm: Screening in Practice – Dr Ben Tran, PeterMaccullum Cancer Centre
440pm: Imaging / Theragnostics in Early Phase Trials – Dr Louise Emmett, St Vincents Hospital
5pm: Westmead experience in I/O phase 1 – Challenges and Solutions – Dr Matteo Carlino, Westmead Hospital
520pm: What we want from an early phase group and what are the metrics we use? - David Fuller, INC Research
540pm: Industry Perspective on early phase trials collaboration – Dr Amanda Goldrick, Amgen